PsA often coexists with a range of comorbidities, which can complicate treatment decisions. By tailoring treatment strategies, clinicians can improve outcomes for their patients.

We’ll discuss the distinct traits of psoriatic arthritis in Black patients, and the various environmental and genetic factors ...

The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

The FDA has accepted Alvotech (ALVO) and Teva's (TEVA) applications for AVT05, their proposed biosimilar to J&J's ...

In a large cohort of patients with autoimmune diseases, treatment with biologic disease-modifying antirheumatic drugs was ...

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

Psoriatic arthritis (PsA) is characterised by several unique clinical ... and tissue levels that form the basis for a new understanding of this relatively common form of inflammatory arthritis. In ...

A West Virginia University legal scholar says current laws may be giving manufacturers of biologic drugs, like antibodies and flu vaccines, too much in the way of legal protections before copycat ...

Healthcare professionals and patients share perspectives on US healthcare hurdles, highlighting the need to improve ...

Alvotech and Teva announced FDA acceptance of the Biologics License Application (BLA) for AVT05, a proposed biosimilar ...

Although Arthritis Today magazine is no longer published, sign up below to receive healthy living tips and resources in our Arthritis Today and other e-newsletters, delivered right to your inbox.